Clinical Trials Logo

Leukemia, Chronic Myeloid clinical trials

View clinical trials related to Leukemia, Chronic Myeloid.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02973711 Withdrawn - Clinical trials for Leukemia, Chronic Myeloid

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Start date: January 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study combines two drugs (ruxolitinib and the tyrosine kinase inhibitor, nilotinib) in an attempt to eliminate the CML (Chronic Myeloid Leukemia) stem cell population and thus allow for the deepest and most durable response possible in patients with CML in chronic phase who have achieved a complete hematologic remission (CHR), complete cytogenetic remission (CCyR), and major molecular remission (MMR), but not a complete molecular remission (CMR). The study will look at safety and tolerability of ruxolitinib when combined with nilotinib in a phase I study and will help establish the MTD (Maximum Tolerated Dose) of ruxolitinib when combined with nilotinib. Once the optimal dose of ruxolitinib is established in the phase I setting, a phase II evaluation will seek to establish the efficacy of this combination.